RNA Therapeutics 2017 London, England, UK 22-23 February 2017

Description:
SMi’s 8th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates and interactive workshops tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.

This exciting programme for 2017 will showcase new developments through clinical and pre-clinical results in topics such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing.

Join us next February to expand your scientific horizons on emerging concepts in nanoparticle delivery systems, small activating RNA and 3rd generation antisense technology. Plus, we’ll be honing in on under-met areas such as targeted delivery beyond the liver, and offering regulatory guidance on the reporting of clinical data through an exclusive MHRA keynote.

Speakers include:

•Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
•John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
•Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA
•Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
•Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis
•Steve Hood, Director, Bioimaging, GSK
•David Giljohann, CEO, Exicure
•Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals
•Amotz Shemi, CEO, Silenseed

Prices:
Conference + Workshop: GBP 2098
Conference only: GBP 1499

Time: 8:30 am to 5:00 pm